ScholarIQanswers from OpenAlex & ORCID
Michael A. Morse
ResearcherPublications, citations & collaboration network
Michael A. Morse is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael A. Morse have?
ScholarIQindexed works
Michael A. Morse has 550 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael A. Morse have?
ScholarIQcitation count
Michael A. Morse has 28,506 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael A. Morse?
ScholarIQh-index
Michael A. Morse has an h-index of 82 in OpenAlex.
What is the i10-index of Michael A. Morse?
ScholarIQi10-index
Michael A. Morse has an i10-index of 282 in OpenAlex.
What is the ORCID of Michael A. Morse?
ScholarIQorcid
The ORCID for Michael A. Morse is on the source record.
What is the OpenAlex record for Michael A. Morse?
ScholarIQopenalex
The OpenAlex for Michael A. Morse is on the source record.
What are the most-cited papers on Michael A. Morse?
ScholarIQmost cited works
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Christine H. Chung, Beloo Mirakhur, Emily Chan, Quynh‐Thu Le, Jordan Berlin, Michael A. Morse, Barbara A. Murphy, Shama M. Satinover, Jacob D. Hosen, David Mauro, Robbert J.C. Slebos, Qinwei Zhou, Diane R. Gold, Tina Hatley, Daniel J. Hicklin, Thomas A.E. Platts‐Mills
Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi, Tim F. Greten, Todd S. Crocenzi, Gregory M. Springett, Michael A. Morse, Herbert J. Zeh, Deirdre Jill Cohen, Robert L. Fine, Beth Onners, Jennifer N. Uram, Daniel A. Laheru, Eric R. Lutz, Sara Solt, Aimee Murphy, Justin Skoble, Ed Lemmens, John Grous, Thomas W. Dubensky, Dirk G. Brockstedt, Elizabeth M. Jaffee
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
Edward M. Wolin, Barbara Jarząb, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David R. Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Li Jiang, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell‐Price, Wasat Mansoor, Kjell Öberg
Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States
Kiran K. Turaga, Edward A. Levine, Rita Barone, Robert P. Sticca, Nicholas J. Petrelli, Laura Lambert, Garrett M. Nash, Michael A. Morse, R. Adbel-Misih, H. Richard Alexander, Fadi F. Attiyeh, David L. Bartlett, Augusto J. Bastidas, Tamar Blazer, Quyen D. Chu, Ki Y. Chung, Luis Manuel Domínguez-Parra, N. Joseph Espat, Jason M. Foster, Keith F. Fournier, R. García, Martin Goodman, Nader Hanna, Lawrence E. Harrison, R. Hoefer, Matthew P. Holtzman, John M. Kane, Daniel M. Labow, Бин Ли, Andrew M. Lowy, Paul Mansfield, Evelyn Ong, Colette Pameijer, James Pingpank, M. Quinones, Richard E. Royal, George I. Salti, Armando Sardi, Perry Shen, Joseph J. Skitzki, James E. Spellman, John H. Stewart, Jesús Esquivel